OVERVIEW
Protalex (OTC:PRTX) is a biotechnology company developing a novel, new class of drugs for the treatment of various autoimmune disorders.
The company’s lead compound, PRTX-100, is currently in development for idiopathic thrombocytopenic purpura, a rare blood clotting disorder, and rheumatoid arthritis. PRTX-100, a highly-purified form of Staphylococcal Protein A (SpA or Protein A) has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. Protalex believes that direct administration of PRTX-100 via I.V. bolus will prove a much more effective therapy for these and other indications.
Protalex is building a strong proprietary position with multiple patents pending; chief among them is the “Protein A Compositions and Methods of Use” patent which was filed with the U.S. Patent and Trademark Office in April 2002. This broad use patent protects the company’s lead compound PRTX-100 for treatment of a variety of autoimmune diseases in addition to idiopathic thrombocytopenic purpura and rheumatoid arthritis, providing a significant barrier to entry for others. The Company has also filed for foreign protection relating to this patent in Canada, Japan and the European Union. Additionally, patent applications relating to the manufacturing process of PRTX-100 and new compounds are currently in process.
Protalex is headquartered in New Hope, Pennsylvania. The Company currently has 10 full-time employees engaged in R&D, clinical research, management and administrative functions.
 |
Protalex Investor Factsheet (pdf 370kb) |